Standard strategies for acute ischemic stroke within the rtPA therapeutic window Brazil

On December 14, 1995, the New England Journal of Medicine published the results of the National Institute of Neurological Disorders and Stroke trial1 and suddenly neurologists from all over the world have started the war against stroke using IV recombinant tissue plasminogen activator (rtPA) within the first 3 hours of stroke onset as their first and strongest weapon against stroke.